Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect

BACKGROUND: Oral bosentan is an established treatment for pulmonary arterial hypertension (PAH). OBJECTIVE: To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). PATIENTS: 22 patients with CHD related PAH (...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: D'Alto, M, Vizza, C D, Romeo, E, Badagliacca, R, Santoro, G, Poscia, R, Sarubbi, B, Mancone, M, Argiento, P, Ferrante, F, Russo, M G, Fedele, F, Calabrò, R
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2007
Témata:
Pulmonary Hypertension
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1955562/
https://ncbi.nlm.nih.gov/pubmed/17135220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/hrt.2006.097360
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky